Near the start of this year, Mimedx Group Inc. looked poised to stretch up toward a $2 billion valuation. But it has struggled to right itself all year, since in February it became clear that the regenerative and therapeutic biologics maker was subject to a U.S. Department of Justice (DoJ) investigation of its sales and marketing practices, including undisclosed payments to doctors.